NCT04233437View on ClinicalTrials.gov

Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

February 10, 2020

Primary Completion Date

May 16, 2020

Study Completion Date

May 16, 2020

Conditions
Stroke
Interventions
DRUG

MLC1501

MLC1501 capsules (4 capcules (2000 mg) twice a day)

DRUG

CYP Cocktail

Repaglinide 0.25 mg, caffeine 100 mg, warfarin 10 mg (with vitamin K), omeprazole 40 mg, dextromethorphan 30 mg, midazolam 2 mg

DRUG

Transporter Cocktail

Digoxin 0.25 mg, furosemide 1 mg, metformin 10 mg, rosuvastatin 10 mg

Trial Locations (1)

3004

Nucleus Network, Melbourne

All Listed Sponsors
collaborator

Moleac Australia Pty Ltd

UNKNOWN

lead

Moleac Pte Ltd.

INDUSTRY

NCT04233437 - Drug-Drug Interaction Study of MLC1501 Using Cocktail of Drugs Acting as Sensitive Clinical Probes/Substrates of Cytochrome P450 Isoenzymes and Transporters in Healthy Subjects | Biotech Hunter | Biotech Hunter